Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.

Sun B, Sengupta N, Rao A, Donnelly C, Waichale V, Roy AS, Ramaswamy S, Pathak D, Bowsher RR, Raiter Y, Aubonnet P, Barve A.

Open source

DOI: 10.1186/s12902-021-00797-4
Published: 2021-06-26
Container: BMC Endocr Disord
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12902-021-00797-4,
  title = {Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.},
  author = {Sun B and  Sengupta N and  Rao A and  Donnelly C and  Waichale V and  Roy AS and  Ramaswamy S and  Pathak D and  Bowsher RR and  Raiter Y and  Aubonnet P and  Barve A.},
  year = {2021},
  journal = {BMC Endocr Disord},
  doi = {10.1186/s12902-021-00797-4},
  url = {https://doi.org/10.1186/s12902-021-00797-4}
}

RIS

TY  - JOUR
TI  - Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
AU  - Sun B
AU  -  Sengupta N
AU  -  Rao A
AU  -  Donnelly C
AU  -  Waichale V
AU  -  Roy AS
AU  -  Ramaswamy S
AU  -  Pathak D
AU  -  Bowsher RR
AU  -  Raiter Y
AU  -  Aubonnet P
AU  -  Barve A.
PY  - 2021
JO  - BMC Endocr Disord
DO  - 10.1186/s12902-021-00797-4
UR  - https://doi.org/10.1186/s12902-021-00797-4
ER  -

APA

B, S., N, S., A, R., C, D., V, W., AS, R., S, R., D, P., RR, B., Y, R., P, A., & A., B. (2021). Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.. BMC Endocr Disord. https://doi.org/10.1186/s12902-021-00797-4

Source records

europe-pmc · retrieved 2026-09-26T07:52:21.445Z
doaj · retrieved 2026-09-26T07:52:21.427Z